AgeX Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

AgeX Therapeutics şirketinin toplam hissedar öz sermayesi $5.4M ve toplam borcu $4.4M olup, bu da borç-öz sermaye oranını 81.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $12.0M ve $6.6M dir.

Anahtar bilgiler

81.5%

Borç/özkaynak oranı

US$4.37m

Borç

Faiz karşılama oranı	n/a
Nakit	US$345.00k
Eşitlik	US$5.36m
Toplam yükümlülükler	US$6.61m
Toplam varlıklar	US$11.97m

Son finansal sağlık güncellemeleri

Recent updates

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

Feb 09

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Nov 20

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: AGE 'nin kısa vadeli varlıkları ( $754.0K ) kısa vadeli yükümlülüklerini ( $5.9M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: AGE şirketinin kısa vadeli varlıkları ( $754.0K ) uzun vadeli yükümlülüklerini ( $693.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: AGE 'nin net borç/öz sermaye oranı ( 75% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: AGE şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 81.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: AGE şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 5.6 oranında tarihsel oranda büyümeye devam ederse AGE un bir yıldan az nakit akışı süresi vardır.

AgeX Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Agex Therapeutics Provides Non-Compliance Update Related to Stock Holders Equity

AgeX Therapeutics Announces Appeal of NYSE American Determination

NYSE American to Suspend Trading Immediately in Agex Therapeutics and Commence Delisting Proceedings

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Recent updates

Serina Therapeutics, Inc. completed the acquisition of AgeX Therapeutics, Inc. (NYSEAM:AGE) from a group of shareholders in a reverse merger transaction.

AgeX Therapeutics, Inc. Appoints Steven Mintz as a Director, Member of Audit Committee, Compensation Committee and Nominating & Corporate Governance Committee

Agex Therapeutics, Inc. Terminates Nafees Malik as Chief Operating Officer, Effective on December 27, 2023

AgeX Therapeutics, Inc., Annual General Meeting, Dec 13, 2023

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Serina Therapeutics, Inc. entered into a merger agreement to acquire AgeX Therapeutics, Inc. (NYSEAM:AGE) from shareholders in a reverse merger transaction.

Agex Therapeutics Provides Non-Compliance Update Related to Stock Holders Equity

AgeX Therapeutics Announces Appeal of NYSE American Determination

NYSE American to Suspend Trading Immediately in Agex Therapeutics and Commence Delisting Proceedings

Third quarter 2022 earnings released: US$0.064 loss per share (vs US$0.052 loss in 3Q 2021)

AgeX Therapeutics, Inc., Annual General Meeting, Dec 07, 2022

Second quarter 2022 earnings released: US$0.069 loss per share (vs US$0.065 loss in 2Q 2021)

AgeX Therapeutics, Inc. Announces Board Changes

First quarter 2022 earnings released: US$0.071 loss per share (vs US$0.053 loss in 1Q 2021)

Full year 2021 earnings released: US$0.23 loss per share (vs US$0.29 loss in FY 2020)

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. to Report Q4, 2021 Results on Mar 29, 2022

AgeX Therapeutics, Inc. announced that it expects to receive $13.16 million in funding from Juvenescence Ltd.

Less than half of directors are independent

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

Third quarter 2021 earnings released: US$0.052 loss per share (vs US$0.067 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.065 loss per share (vs US$0.071 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.053 loss per share (vs US$0.085 loss in 1Q 2020)

Full year 2020 earnings released: US$0.29 loss per share (vs US$0.33 loss in FY 2019)

Agex Therapeutics to Collaborate with the Ohio State University to Generate Proof-Of-Concept Animal Data for Agex’s Brown Adipose Tissue (Bat) Cell Therapy Candidate for Diabetes and Obesity

Atlas Capital Group Ltd. entered into an agreement to acquire LifeMap Sciences Ltd from AgeX Therapeutics, Inc. (AMEX:AGE).

Here's What AgeX Therapeutics, Inc.'s (NYSEMKT:AGE) Shareholder Ownership Structure Looks Like

New 90-day high: US$2.06

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

New 90-day high: US$1.94

AgeX Therapeutics, Inc., Annual General Meeting, Dec 28, 2020

Does AgeX Therapeutics' (NYSEMKT:AGE) Share Price Gain of 14% Match Its Business Performance?

Third quarter 2020 earnings released: US$0.067 loss per share

New 90-day high: US$2.48

First half earnings released

New 90-day high - US$1.52

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 2000 Dynamic Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell 3000 Growth Index

AgeX Therapeutics, Inc.(AMEX:AGE) dropped from Russell Microcap Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin